Clinical factors influencing retreatment with anti-PD-(L)1 therapies after treatment in early-stage cancers: a modified Delphi consensus study

Clinical factors influencing retreatment with anti-PD-(L)1 therapies after treatment in early-stage cancers: a modified Delphi consensus study

Anti-programmed death (ligand) 1 (anti-PD-(L)1) therapies were first introduced in the metastatic setting and have since been approved and reimbursed for treating early-stage cancers in the adjuvant, perioperative, and neoadjuvant settings in many cancer types. Current evidence supporting anti-PD(L)...

Full description

Saved in:
Bibliographic Details
Main Authors: Christos Chouaïd, Lajos Pusztai, Federico Cappuzzo, Phillip Parente, Robert Jones, Vernon K Sondak, Masayoshi Nagata, Raquel Aguiar-Ibáñez, Yosuke Hirasawa, Ryuichi Mizuno, Smita Kothari, Carmel Spiteri, Alexander Sun, Chris Elder, Masaru Ishida, Seung Hyeun Lee, David Okonji, Bhavesh Shah, Dominihemberg Ferreira, Andrea Lauer, Amrit Kaliasethi, Carol Kao, Jan McKendrick
Format: Article
Language:English
Published: BMJ Publishing Group 2025-05-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/5/e011184.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/13/5/e011184.full

Similar Items